Adults with active psoriatic arthritis have a new treatment option, and its most distinctive feature is not the molecule but how it is given. On 30 October 2026 Sun Pharmaceutical Industries announced that the U.S. Food and Drug Administration (FDA) had approved a supplemental Biologics License Application for Ilumya (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis. Ilumya is an interleukin-23 (IL-23) inhibitor first approved in 2018 for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. With this approval it becomes the third IL-23 inhibitor approved for psoriatic arthritis in the United States, and, according to Sun Pharma, the only one given exclusively by a healthcare provider.
What the Approval Adds
Psoriatic arthritis is a chronic immune-related disease that causes swelling, pain and stiffness in joints and in entheses, the places where tendons and ligaments connect to bones. It can develop at any age, and it can occur regardless of how severe a person's psoriasis is. Sun Pharma estimates that as many as 2.4 million Americans live with the condition, and says that roughly 1 in 3 people living with psoriasis also have psoriatic arthritis, while more than 15% of people living with psoriasis may have undiagnosed psoriatic arthritis. Ilumya is a humanised monoclonal antibody designed to bind selectively to the p19 subunit of IL-23 and block its interaction with the IL-23 receptor, reducing the release of pro-inflammatory signals. The recommended dose for psoriatic arthritis is a 100 mg subcutaneous injection at weeks 0 and 4, followed by dosing every 12 weeks, given by a healthcare provider rather than self-administered at home. Sun Pharma's North America chief executive, Rick Ascroft, said the provider-administered model makes Ilumya an option for adults who are unable to self-administer treatment or who may benefit from regular in-office care.
What the Trials Showed
The approval is supported by two phase 3 studies, INSPIRE-1 and INSPIRE-2, which were 52-week, global, multicentre, randomised, double-blind, placebo-controlled studies of tildrakizumab 100 mg in adults with active psoriatic arthritis. Together they enrolled more than 800 adults. INSPIRE-1 enrolled 510 participants who had previously been treated with an anti-TNF agent, while INSPIRE-2 enrolled 296 participants who had not previously received anti-TNF treatment. Patients were randomly assigned to tildrakizumab 100 mg or placebo and could use methotrexate or leflunomide as needed. In both studies the primary endpoint was met: at 24 weeks, significantly more patients receiving tildrakizumab met the endpoint of a 20% improvement in American College of Rheumatology response criteria (ACR20) compared with placebo. Neither the company announcement nor the Medscape report gives the actual response rates, so this article does not quote them. The safety profile in the studies was consistent with the drug's established profile in plaque psoriasis, and no new safety signals were identified. The most common adverse reactions in psoriatic arthritis, occurring in at least 3% of patients, were upper respiratory tract infections and COVID-19. Ilumya may increase the risk of infection, patients should be evaluated for tuberculosis before starting treatment, and treatment should not be given to patients with active tuberculosis or started in patients with a clinically important active infection until it resolves.
Why This Matters for Healthcare Organizations
For dermatology and rheumatology practices, the practical question is which patients benefit from an in-office model. A provider-administered injection creates a regular point of contact, which can help with adherence checks, screening and follow-up, and it removes the burden of self-injection for patients who struggle with it. It also creates scheduling and capacity work: every 12 weeks after the first two doses, a patient needs an appointment, a clinician and a recorded administration, and the practice needs a process for tuberculosis evaluation, infection screening and immunisation review before treatment starts. Referral pathways matter too, since patients with psoriasis who develop joint symptoms may first present in dermatology or primary care and need a timely rheumatology assessment rather than a long wait. Practices should also be ready for payer conversations, since a new indication does not by itself settle coverage or prior authorisation for any individual patient, and the company announcement does not address pricing or launch timing.
Analysis: The Difference Is Delivery, Not a New Mechanism
This approval does not introduce a new mechanism to psoriatic arthritis care. IL-23 inhibition is already established in this condition, with guselkumab approved in 2020 and risankizumab in 2022. What Ilumya adds is a delivery choice, and that choice will matter more to some patients than to others. For a patient who injects confidently at home, an in-office schedule may feel like an unnecessary trip. For a patient who cannot self-inject, who misses doses, or who values regular contact with a care team, the same schedule may be the reason treatment works. The approval is therefore best read as widening the range of ways a proven approach can be delivered, rather than as a breakthrough in itself. Its real-world value will depend on the unglamorous details: whether practices can fit the injection visits into their schedules, whether payers cover the new indication without long delays, and whether the patients who need in-office care are the ones who actually get referred.
Clinics adding new treatment pathways and the appointment, screening and follow-up work that comes with them can explore MedClinicX's AI patient portal, see how after-hours calls are handled on our AI medical receptionist page, or explore the demos and request a quote for their own practice.
Sources and References
- Sun Pharmaceutical Industries via PR Newswire — ILUMYA (tildrakizumab-asmn) approved in the U.S. for the treatment of adults with active psoriatic arthritis, 30 October 2026: https://www.prnewswire.com/news-releases/ilumya-tildrakizumab-asmn-approved-in-the-us-for-the-treatment-of-adults-with-active-psoriatic-arthritis-302924320.html
- Medscape Medical News — FDA Approves Tildrakizumab for Psoriatic Arthritis in Adults, 30 October 2026: https://www.medscape.com/viewarticle/fda-approves-tildrakizumab-psoriatic-arthritis-adults-2026a10015fb?src=
Reporting based on the sources above, accessed 31 October 2026. The Sun Pharma announcement and the Medscape report were read directly in full and cross-checked against each other. MedClinicX did not conduct original reporting or interviews for this article. This article is for information only and is not medical advice. Corrections: contact us via https://medclinicx.com/contact